Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach.

Journal Information

Full Title: Front Cardiovasc Med

Abbreviation: Front Cardiovasc Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Cardiac & Cardiovascular Systems

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest GM: Fulltime employee and shareholder of Abbott Laboratories. CF: Consulting: Abbott, FujiRebio, Quidel:Ortho, Roche Diagnostics, Siemens. Speaker: Pathfast. Grants/contracts as PI: Abbott, FujiRebio, Quidel:Ortho, Roche Siemens, NIH. Adjudication committee: Siemens, Tosoh. Patent: #10509044, Methods for assessing differential risk for developing heart failure. AB: Advisory board: Astra-Zeneca, DSMB: CTI Biopharma. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

Evidence found in paper:

"The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025